Momelotinib: Side Effects, Uses & Monitoring
OJJAARA is indicated for the treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF or secondary MF [post‑polycythemia vera (PV) and post‑essential thrombocythemia (ET)], in adults with anemia.
- Data source
- FDA labeling via NIH DailyMed (label 4a672fd1…)
- Label version
- current
- Last reviewed
- 2026
Reported adverse reactions
Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.
No structured frequency data available in current labeling. Consult the official label.
Labeled uses (from FDA prescribing information)
OJJAARA is indicated for the treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF or secondary MF [post‑polycythemia vera (PV) and post‑essential thrombocythemia (ET)], in adults with anemia.
Conditions associated with Momelotinib in labeling
Anemia
A condition in which the blood has a lower than normal number of red blood cells or hemoglobin, reducing oxyge...
Essential thrombocythemia
Essential thrombocythemia is a medical condition that may be associated with various symptoms and signs....
Polycythemia vera
Polycythemia vera is a medical condition that may be associated with various symptoms and signs....
Frequently Asked Questions
What is Momelotinib used for?
FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.
What are the most commonly reported side effects of Momelotinib?
Current labeling for this ingredient does not include a structured frequency table that we can reproduce. Review the official label linked below.
Does Momelotinib require lab monitoring?
Monitoring needs vary. Ask your healthcare provider whether any lab tests apply while taking Momelotinib.
Where does this information come from?
All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.
Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.